Acid reflux statistics vary because studies measure different things: recurring symptoms, diagnosed gastroesophageal reflux disease (GERD), or visible esophageal injury. Across the supplied research, estimates range from 2.5% for reflux symptoms in China to 51.2% in Greece, while a global meta-analysis estimated pooled GERD prevalence at 13.98%.
Contents
- How common is acid reflux?
- Regional GERD prevalence
- Symptoms and healthcare use in the United States
- Risk factors linked with reflux
- What studies found in Asia
- Endoscopic findings and reflux esophagitis
- Barrett’s esophagus among people with GERD
How common is acid reflux?
The clearest global estimate in the supplied research comes from Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease: Systematic Review with Meta-analysis. It estimated pooled GERD prevalence at 13.98% worldwide. The same meta-analysis estimated prevalence at 19.55% in North America and 12.88% in Latin America and the Caribbean. Country-level estimates ranged from 4.16% in China to 22.40% in Turkey.
These figures are estimates for GERD, not a count of everyone who has occasional heartburn. A separate source, Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis, measured weekly heartburn or regurgitation and found a pooled prevalence of 13.3%. In that analysis, reflux-symptom prevalence was 2.5% in China and 51.2% in Greece.
The difference between 13.98% pooled GERD prevalence and 13.3% pooled weekly symptom prevalence should not be treated as a precise trend. The studies used different definitions, populations, and methods. It does show why an acid reflux statistic needs its measurement definition and geography alongside the percentage.
An earlier 2005 review, Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review, reported North American GERD prevalence estimates from 18.1% to 27.8%. Its European estimates ranged from 8.8% to 25.9%, while estimates in East Asia ranged from 2.5% to 7.8%. The same review reported a broader Middle Eastern range of 8.7% to 33.1%, a prevalence of 11.6% in Australia, and 23.0% in South America.
Selected prevalence estimates
| Measure or location | Estimate | Source or period |
|---|---|---|
| GERD worldwide | 13.98% | Global meta-analysis |
| GERD in North America | 19.55% | Global meta-analysis |
| GERD in Latin America and the Caribbean | 12.88% | Global meta-analysis |
| Weekly heartburn or regurgitation worldwide | 13.3% | Global symptom meta-analysis |
| GERD in China | 4.16% | Global meta-analysis |
| GERD in Turkey | 22.40% | Global meta-analysis |
| Reflux symptoms in China | 2.5% | Global symptom meta-analysis |
| Reflux symptoms in Greece | 51.2% | Global symptom meta-analysis |
Regional GERD prevalence
The 2005 epidemiology review also estimated GERD incidence, which is different from prevalence. In the overall UK and U.S. populations, incidence was about 5 cases per 1,000 person-years. Among UK children aged 1–17 years, the review estimated incidence at 0.84 cases per 1,000 person-years. Person-years account for both the number of people observed and the length of observation; they should not be read as a percentage of a population.
The weekly symptom meta-analysis found that people aged 50 years and older had higher odds of reflux symptoms, with an odds ratio (OR) of 1.32. An OR above 1 indicates higher odds in the reported comparison, but it is not itself a percentage-point increase and does not establish that age alone caused symptoms.
The Swedish population study Prevalence of gastro-oesophageal reflux symptoms and the influence of age and sex found total reflux-symptom prevalence of 31.4%. It classified 26.0% as having minor symptoms and 5.4% as having severe symptoms. Symptoms occurred at least weekly in 11.6% of the Swedish study population. These categories are not additive measures of separate diseases; they describe the symptom distribution reported by that study.
Symptoms and healthcare use in the United States
The NIDDK publication Digestive Diseases Statistics for the United States reported that reflux symptoms occurring at least weekly affected 20% of the U.S. population in 2004. This is a historical estimate for that measurement year, not a current U.S. prevalence figure.
The same NIDDK source reported 64.6 million GERD prescriptions in the United States in 2004. It recorded 8.9 million GERD ambulatory care visits in 2009 and 4.7 million GERD hospitalizations in 2010. In 2010, the source recorded 1,653 U.S. deaths associated with GERD.
Those counts describe healthcare activity and mortality recorded for specific years. They should not be combined into a single estimate of how many people had acid reflux: a prescription, outpatient visit, hospitalization, and death are different events, and the dates are not the same.
Risk factors linked with reflux
The global symptom meta-analysis reported higher odds of reflux symptoms among smokers, with OR 1.26. NSAID or aspirin users had OR 1.44, and obese individuals had OR 1.73. The analysis also reported OR 1.32 for people aged 50 years and older. These are associations from the cited analysis, not guarantees that an individual with one factor will develop reflux.
The study Risk factors associated with symptoms of gastroesophageal reflux found several additional associations with frequent reflux symptoms. A body mass index above 30 kg/m2 was associated with OR 2.8. Having an immediate family member with heartburn or esophageal or stomach disease was associated with OR 2.6. A past history of smoking was associated with OR 1.6, while consuming more than seven drinks per week was associated with OR 1.9. A higher psychosomatic symptom checklist score was associated with OR 1.4 for each 5-unit increase.
Another analysis, Adiposity, diabetes, lifestyle factors and risk of gastroesophageal reflux disease: a Mendelian randomization study, reported OR 1.49 for GERD per one standard-deviation increase in BMI. A one-unit increase in log-transformed type 2 diabetes odds was associated with GERD odds of OR 1.07. A one-standard-deviation increase in smoking-initiation prevalence was associated with OR 1.41.
The methods differ across these studies. The frequent-symptom study reports observational associations for defined exposures, while the Mendelian randomization study uses genetic instruments and reports effects on odds under its own assumptions. Their odds ratios should therefore be read as study-specific estimates rather than a ranked list of personal risk.
What studies found in Asia
Japan’s results vary substantially with the measurement method. Systematic review of the epidemiology of gastroesophageal reflux disease in Japan reported at-least-weekly GERD symptom prevalence between 6.5% and 9.5% across seven studies. Two studies that included upper gastrointestinal endoscopy reported at-least-weekly symptom prevalence of 19.0% and 21.8%.
Japanese studies using the QUEST symptom score reported prevalence from 10.2% to 29.0%. Frequency-scale studies reported 27.0% to 37.6%, while studies reporting reflux symptoms without defining frequency reported 15.1% to 24.3%. Across six Japanese studies, reflux esophagitis prevalence ranged from 4.9% to 8.2%.
In China, A population-based survey of the epidemiology of symptom-defined gastroesophageal reflux disease: the Systematic Investigation of Gastrointestinal Diseases in China reported overall symptom-defined GERD prevalence of 3.1%. City estimates ranged from 1.7% in Guangzhou to 5.1% in Wuhan. Prevalence was 2.4% in urban areas and 3.8% in rural areas.
The differences within Japan and China reinforce the importance of definitions and sampling. A symptom score, a frequency threshold, endoscopy, and a population survey can identify overlapping but not identical groups.
Endoscopic findings and reflux esophagitis
Endoscopic studies measure visible esophageal injury rather than symptoms alone. In Clinical spectrum of reflux esophagitis among 25,536 Koreans who underwent a health check-up, reflux esophagitis prevalence was 7.91% among the 25,536 adults undergoing health checks. Los Angeles grade A (LA-A) accounted for 5.87% of participants, LA-B for 1.84%, LA-C for 0.18%, and LA-D for 0.02%.
Another Korean study, Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria, reported reflux esophagitis prevalence of 12.0% in 2,359 subjects with erosive disease and non-erosive reflux disease prevalence of 3.1%. Because the study populations and disease definitions differ, these values are not a direct time trend against the Korean health-check estimate.
The review Systematic review: patterns of reflux-induced symptoms and esophageal endoscopic findings in large-scale surveys reported reflux esophagitis prevalence of 15.5% in Kalixanda, 11.8% in Loiano-Monghidoro, and 6.4% in SILC. In health-check studies from Japan, China, and Korea, reflux esophagitis prevalence ranged from 3.4% to 8.5%.
Taiwan health-check studies in the same review reported a higher mean prevalence of 15.6%, with a range from 9.0% to 24.6%. Among people without symptom-defined GERD, reflux esophagitis in health-check studies ranged from 1.6% to 22.8%. That finding is one reason symptoms and endoscopic results should be reported separately.
Barrett’s esophagus among people with GERD
The meta-analysis Prevalence of Barrett’s Esophagus and Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-Analysis estimated pooled Barrett’s esophagus prevalence at 7.0% among people with GERD. Among people without GERD, pooled prevalence was 2.2% overall.
In low-risk-of-bias population screening studies, Barrett’s esophagus prevalence among people without GERD was 4.9%. This higher screening estimate illustrates how study design and participant selection can change a pooled result. The figures describe prevalence in the populations studied; they do not predict an individual’s diagnosis or establish that reflux caused every case.